Cargando…

Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action

Zinc (Zn) was found to enhance the antidepressant efficacy of imipramine (IMI) in human depression and animal tests/models of depression. However, the underlying mechanism for this effect remains unknown. We measured the effect of intragastric (p.o.) combined administration of IMI (60 mg/kg) and Zn...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafało-Ulińska, Anna, Poleszak, Ewa, Szopa, Aleksandra, Serefko, Anna, Rogowska, Magdalena, Sowa, Ireneusz, Wójciak, Magdalena, Muszyńska, Bożena, Krakowska, Agata, Gdula-Argasińska, Joanna, Kała, Katarzyna, Jasiewicz, Barbara, Opoka, Włodzimierz, Szewczyk, Bernadeta, Nowak, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551732/
https://www.ncbi.nlm.nih.gov/pubmed/32825449
http://dx.doi.org/10.3390/nu12092529
_version_ 1783593244460843008
author Rafało-Ulińska, Anna
Poleszak, Ewa
Szopa, Aleksandra
Serefko, Anna
Rogowska, Magdalena
Sowa, Ireneusz
Wójciak, Magdalena
Muszyńska, Bożena
Krakowska, Agata
Gdula-Argasińska, Joanna
Kała, Katarzyna
Jasiewicz, Barbara
Opoka, Włodzimierz
Szewczyk, Bernadeta
Nowak, Gabriel
author_facet Rafało-Ulińska, Anna
Poleszak, Ewa
Szopa, Aleksandra
Serefko, Anna
Rogowska, Magdalena
Sowa, Ireneusz
Wójciak, Magdalena
Muszyńska, Bożena
Krakowska, Agata
Gdula-Argasińska, Joanna
Kała, Katarzyna
Jasiewicz, Barbara
Opoka, Włodzimierz
Szewczyk, Bernadeta
Nowak, Gabriel
author_sort Rafało-Ulińska, Anna
collection PubMed
description Zinc (Zn) was found to enhance the antidepressant efficacy of imipramine (IMI) in human depression and animal tests/models of depression. However, the underlying mechanism for this effect remains unknown. We measured the effect of intragastric (p.o.) combined administration of IMI (60 mg/kg) and Zn (40 mg Zn/kg) in the forced swim test (FST) in mice. The effect of Zn + IMI on serum, brain, and intestinal Zn concentrations; Zn transporter (ZnT, ZIP) protein levels in the intestine and ZnT in the brain; including BDNF (brain-derived neurotrophic factor) and CREB (cAMP response element-binding protein) protein levels in the brain were evaluated. Finally, the effect of IMI on Zn permeability was measured in vitro in colon epithelial Caco-2 cells. The co-administration of IMI and Zn induced antidepressant-like activity in the FST in mice compared to controls and Zn or IMI given alone. This effect correlated with increased BDNF and the ratio of pCREB/CREB protein levels in the prefrontal cortex (PFC) compared to the control group. Zn + IMI co-treatment increased Zn concentrations in the serum and brain compared to the control group. However, in serum, co-administration of IMI and Zn decreased Zn concentration compared to Zn alone treatment. Also, there was a reduction in the Zn-induced enhancement of ZnT1 protein level in the small intestine. Zn + IMI also induced an increase in the ZnT4 protein level in the PFC compared to the control group and normalized the Zn-induced decrease in the ZnT1 protein level in the hippocampus (Hp). The in vitro studies revealed enhanced Zn permeability (observed as the increased transfer of Zn through the intestinal cell membrane) after IMI treatment. Our data indicate that IMI enhances Zn transfer through the intestinal tract and influences the redistribution of Zn between the blood and brain. These mechanisms might explain the enhanced antidepressant efficacy of combined IMI/Zn treatment observed in the FST in mice.
format Online
Article
Text
id pubmed-7551732
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75517322020-10-14 Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action Rafało-Ulińska, Anna Poleszak, Ewa Szopa, Aleksandra Serefko, Anna Rogowska, Magdalena Sowa, Ireneusz Wójciak, Magdalena Muszyńska, Bożena Krakowska, Agata Gdula-Argasińska, Joanna Kała, Katarzyna Jasiewicz, Barbara Opoka, Włodzimierz Szewczyk, Bernadeta Nowak, Gabriel Nutrients Article Zinc (Zn) was found to enhance the antidepressant efficacy of imipramine (IMI) in human depression and animal tests/models of depression. However, the underlying mechanism for this effect remains unknown. We measured the effect of intragastric (p.o.) combined administration of IMI (60 mg/kg) and Zn (40 mg Zn/kg) in the forced swim test (FST) in mice. The effect of Zn + IMI on serum, brain, and intestinal Zn concentrations; Zn transporter (ZnT, ZIP) protein levels in the intestine and ZnT in the brain; including BDNF (brain-derived neurotrophic factor) and CREB (cAMP response element-binding protein) protein levels in the brain were evaluated. Finally, the effect of IMI on Zn permeability was measured in vitro in colon epithelial Caco-2 cells. The co-administration of IMI and Zn induced antidepressant-like activity in the FST in mice compared to controls and Zn or IMI given alone. This effect correlated with increased BDNF and the ratio of pCREB/CREB protein levels in the prefrontal cortex (PFC) compared to the control group. Zn + IMI co-treatment increased Zn concentrations in the serum and brain compared to the control group. However, in serum, co-administration of IMI and Zn decreased Zn concentration compared to Zn alone treatment. Also, there was a reduction in the Zn-induced enhancement of ZnT1 protein level in the small intestine. Zn + IMI also induced an increase in the ZnT4 protein level in the PFC compared to the control group and normalized the Zn-induced decrease in the ZnT1 protein level in the hippocampus (Hp). The in vitro studies revealed enhanced Zn permeability (observed as the increased transfer of Zn through the intestinal cell membrane) after IMI treatment. Our data indicate that IMI enhances Zn transfer through the intestinal tract and influences the redistribution of Zn between the blood and brain. These mechanisms might explain the enhanced antidepressant efficacy of combined IMI/Zn treatment observed in the FST in mice. MDPI 2020-08-20 /pmc/articles/PMC7551732/ /pubmed/32825449 http://dx.doi.org/10.3390/nu12092529 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rafało-Ulińska, Anna
Poleszak, Ewa
Szopa, Aleksandra
Serefko, Anna
Rogowska, Magdalena
Sowa, Ireneusz
Wójciak, Magdalena
Muszyńska, Bożena
Krakowska, Agata
Gdula-Argasińska, Joanna
Kała, Katarzyna
Jasiewicz, Barbara
Opoka, Włodzimierz
Szewczyk, Bernadeta
Nowak, Gabriel
Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action
title Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action
title_full Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action
title_fullStr Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action
title_full_unstemmed Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action
title_short Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action
title_sort imipramine influences body distribution of supplemental zinc which may enhance antidepressant action
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551732/
https://www.ncbi.nlm.nih.gov/pubmed/32825449
http://dx.doi.org/10.3390/nu12092529
work_keys_str_mv AT rafałoulinskaanna imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT poleszakewa imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT szopaaleksandra imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT serefkoanna imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT rogowskamagdalena imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT sowaireneusz imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT wojciakmagdalena imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT muszynskabozena imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT krakowskaagata imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT gdulaargasinskajoanna imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT kałakatarzyna imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT jasiewiczbarbara imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT opokawłodzimierz imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT szewczykbernadeta imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction
AT nowakgabriel imipramineinfluencesbodydistributionofsupplementalzincwhichmayenhanceantidepressantaction